Sadly, I disagree. The huge difference being that neoadjuvant chemoradiation was already the established SOC in esophageal cancer. In Panc, we are don't have an established foothold yet. I think one of the trials is going to have to show that doublet or triplet chemo + RT is better than doublet or triplet chemo alone (either OS or R0) for us to stay in the SOC game. Despite the fact that local progression is a major cause of severe morbidity and the dominant pattern of progression for up to a third of patients, there is a very strongly held belief that pancreatic cancer is a systemic disease and, by extension, chemo has to be better. Given how much FOLFIRINOX improves survival compared to single agent gem across the board (adjuvant to metastatic) I don't see a realistic scenario in which RT replaces it in people minds. It is going to have to add to it.
Personally, I agree with the toxicity argument. In addition to the acute toxicities, long term neuropathy seems to be quite pronounced as well. But I can tell you from a lot of experience it is hard to get anyone, even NIH study sections with corresponding RFAs, interested in toxicity mitigation studies for aggressive cancers like pancreatic. The montra is "find the cure, then worry about side effects."